Promising trial results: AlloNK plus rituximab achieved a 71% ACR50 response rate in mid-stage testing for refractory rheumatoid arthritis, with no treatment-related serious adverse events. Regulatory ...

Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in ...

Boston Scientific has leased the space in Wakad at ₹66.25 per sq ft per month rent ...

Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no pat ...

Initial AlloNK® (AB-101) clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months ...

Veppanu represents a scientific milestone as the first-ever proteolysis-targeting chimera (PROTAC) to receive FDA approval.

Q1 FY2025 earnings: record sales and profit, raised full-year outlook, tariff impact seen at ¥70B, PlayStation and Music strong.

Ashley is a former lead editor of mortgages and loans at Forbes Advisor. She graduated from Utah Tech University with a bachelor’s in English with an emphasis in creative writing. She began her career ...

Ashley is a former lead editor of mortgages and loans at Forbes Advisor. She graduated from Utah Tech University with a bachelor’s in English with an emphasis in creative writing. She began her career ...